Preclinical models of pancreatic ductal adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDA) is one of the most difficult human malignancies to treat. The 5‐year survival rate of PDA patients is 7% and PDA is predicted to become the second leading cancer‐related cause of death in the USA. Despite intensive efforts, the translation of findings in preclinical studies has been ineffective, due partially to the lack of preclinical models that faithfully recapitulate features of human PDA. Here, we review current preclinical models for human PDA (eg human PDA cell lines, cell line‐based xenografts and patient‐derived tumour xenografts). In addition, we discuss potential applications of the recently developed pancreatic ductal organoids, three‐dimensional culture systems and organoid‐based xenografts as new preclinical models for PDA. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 14, 2015
- Source ID
- 10.1002/path.4651
Entities
People
- Chang‐il Hwang
- David A. Tuveson
- Hans Clevers
- Sylvia F Boj
Organizations
- Cold Spring Harbor Laboratory
- Lustgarten Foundation for Pancreatic Cancer Research
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- United States Department of Defense
- University Medical Center Utrecht